MaxCyte (MXCT) Stephens 26th Annual Investment Conference | NASH2024 summary

Strategic focus and organizational changes

• Renewed focus on cell and gene therapy, doubling down on core strengths and industry leadership in non-viral cell engineering platforms.

• Hired a new head of engineering and promoted a new Chief Commercial Officer to unify customer touchpoints and drive product development.

• Streamlined commercial operations and enhanced engineering capabilities to support multiple product offerings and future growth.

• Emphasis on operational excellence and cost structure improvements to position for profitability.

Technology and market differentiation

• Electroporation platform enables high-efficiency, high-viability, non-viral cell engineering, supporting both cell therapy and drug discovery markets.

• Platform is used in the manufacturing of Casgevy, the first non-viral gene-edited approved therapy.

• Over 100 protocols for various cell types, with a focus on T cells and expanding into NK cells, autoimmune diseases, and solid tumors.

• Partnerships with leading biotech firms and regulatory validation through FDA-referenced drug master files in over 60 clinical trials.

Industry trends and market environment

• Cell and gene therapy industry is recovering, with increased clinical and research programs and more funding for near-clinic projects.

• Commercial approvals like Casgevy have validated the field and increased willingness among partners to enter strategic platform licenses (SPLs).

• Majority of industry investment is in T cell therapeutics, with growing interest in autoimmune and solid tumor indications.